BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), today announced encouraging preliminary results of an in vivo animal study which exhibited DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors.
